In multiple different independent patient cohorts, CNST expression of AML patients with various subtypes showed higher expression than normal population, which led us to believe that compared with other AML makers such as CD33 (Nguyen et al., 2006) and CD123 (Muñoz et al., 2001), the increase of expression level of CNST in AML is more common. The gene discussed is CD33; the disease is acute myeloid leukemia.